id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-277576-3dvt6uj7	Demir, Erol	COVID‐19 in kidney transplant recipients: A multicenter experience in Istanbul	2020-07-13		.txt	text/plain	2243	169	51	INTRODUCTION: Management of COVID‐19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy. MATERIAL AND METHODS: Kidney transplant recipients diagnosed with COVID‐19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. [1] [2] [3] [4] [5] [6] [7] Although uremia and kidney transplantation are not considered a risk factor in COVID-19, SARS-CoV-2 often causes a moderate or severe infection in kidney transplant recipients. Kidney transplant recipients diagnosed with COVID-19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. 2, 4, 5 To the best of our knowledge, the use of favipiravir and anakinra in the treatment of COVID-19 in kidney transplant recipients has not been previously reported. In conclusion, COVID-19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients, possibly due to immunosuppressive therapy.	./cache/cord-277576-3dvt6uj7.txt	./txt/cord-277576-3dvt6uj7.txt